1. Home
  2. RF vs UTHR Comparison

RF vs UTHR Comparison

Compare RF & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regions Financial Corporation

RF

Regions Financial Corporation

HOLD

Current Price

$30.79

Market Cap

24.1B

Sector

Finance

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$473.16

Market Cap

20.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RF
UTHR
Founded
1970
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.1B
20.5B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
RF
UTHR
Price
$30.79
$473.16
Analyst Decision
Hold
Buy
Analyst Count
15
12
Target Price
$29.10
$498.83
AVG Volume (30 Days)
15.9M
329.5K
Earning Date
01-16-2026
02-26-2026
Dividend Yield
3.44%
N/A
EPS Growth
19.17
16.08
EPS
2.30
26.38
Revenue
$7,056,000,000.00
$3,128,400,000.00
Revenue This Year
$15.12
$13.57
Revenue Next Year
$3.78
$5.72
P/E Ratio
$13.40
$17.94
Revenue Growth
6.97
13.50
52 Week Low
$17.74
$266.98
52 Week High
$31.17
$519.99

Technical Indicators

Market Signals
Indicator
RF
UTHR
Relative Strength Index (RSI) 69.71 46.17
Support Level $27.59 $462.02
Resistance Level $31.16 $489.50
Average True Range (ATR) 0.64 9.60
MACD 0.24 0.93
Stochastic Oscillator 90.28 41.99

Price Performance

Historical Comparison
RF
UTHR

About RF Regions Financial Corporation

Regions Financial is one of the midsized regional banks in the US, with around $160 billion in total assets as of Sept. 30, 2025. Headquartered in Birmingham, Alabama, Regions Financial has a footprint mostly in the US southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, wealth management, and capital markets.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: